Clinical trial
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate…
NCT02952534 · pharmaand GmbH, Industry · Completed
Key facts
| NCT number | NCT02952534 |
|---|---|
| Title | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency |
| Official title | TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency |
| Acronym | TRITON2 |
| Lead sponsor | pharmaand GmbH, Industry |
| Collaborators | Foundation Medicine Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Castration Resistant Prostate Cancer |
| Intervention type | Drug |
| Interventions | Rucaparib |
| Enrollment | 277 |
| Start date | Feb 15, 2017 |
| Primary completion | Jul 18, 2021 |
| Completion | Jul 27, 2021 |
| First posted | Nov 2, 2016 |
| Last update posted | Jun 9, 2023 |
| Countries | Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: